CME/CE - MedEd On The Go

Episodes 33-48 of 380

MinuteCE®
Reperfusion Paradox: The Hidden Threat in STEMI After PCI and the Quest for Effective Therapeutics
0.50 credits 4 episodes
- Manesh R. Patel, MD
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
0.50 credits 4 episodes
Biomarkers of the Storm: Decoding IRI’s Signature
Biomarkers of the Storm: Decoding IRI’s Signature
MinuteCE®
Biomarkers of the Storm: Decoding IRI’s Signature
0.50 program credits
- Manesh R. Patel, MD
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
0.50 program credits
What’s on the Horizon for IRI Management?
What’s on the Horizon for IRI Management?
MinuteCE®
What’s on the Horizon for IRI Management?
0.50 program credits
- Manesh R. Patel, MD
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
0.50 program credits
The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality
The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality
MinuteCE®
The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality
0.50 program credits
- Manesh R. Patel, MD
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
0.50 program credits
Unveiling the Reperfusion Paradox
Unveiling the Reperfusion Paradox
MinuteCE®
Unveiling the Reperfusion Paradox
0.50 program credits
- Manesh R. Patel, MD
0.50 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Pediatric Narcolepsy: Timely Diagnosis, Treatment, and Outcome Optimization
Pediatric Narcolepsy: Timely Diagnosis, Treatment, and Outcome Optimization
CME/CE
Pediatric Narcolepsy: Timely Diagnosis, Treatment, and Outcome Optimization
1.00 credit
- Anne Marie Morse, DO, FAASM
1.00 credit
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Medical Therapy: Antithrombotic Management of PAD—What Has Changed?
Medical Therapy: Antithrombotic Management of PAD—What Has Changed?
MinuteCE®
Medical Therapy: Antithrombotic Management of PAD—What Has Changed?
1.00 program credit
- Marc P. Bonaca, MD, MPH
- Manesh R. Patel, MD
1.00 program credit

3/8